MLICM
NMRA icon

Metropolitan Life Insurance Company (MetLife)’s Neumora Therapeutics NMRA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-921
Closed -$12.7K – 1382
2024
Q1 		$12.7K Hold
921
– – ﹤0.01% 2045
2023
Q4 		$15.7K Buy
+921
New +$11.3K ﹤0.01% 2020

Other funds holding NMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s NMRA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Neumora Therapeutics (NMRA) in Q2 2024, closing a stake of 921 shares — an estimated $12.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in NMRA in Q4 2023 and held it in 2 quarters. The position peaked at $15.7K in Q4 2023. 93 funds tracked by Wall St. Rank hold NMRA as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Neumora Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 921 Neumora Therapeutics shares in Q2 2024, an estimated $12.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Neumora Therapeutics in Q4 2023 and held it in 2 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Neumora Therapeutics position peaked at $15.7K in Q4 2023.
  • 93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.